Transforming Your Capabilities.
We provide the seamless integration of GI research into your practice to broaden your offerings, enhance care for your patients, and increase your support for referring physicians.
Transforming Your Research.
With premier integrated research partnerships across the country, we can offer a program supported by embedded study teams, leading to greater patient access at the point of care.
Transforming Your Outlook.
We are studying NASH and other diseases with the aim of developing new therapies to address growing problems and improve your overall health.
Let’s work together.
We’re taking on NASH with strong research partnerships and innovative approaches that leverage a proven platform. You can be part of it.
Studies Show Increased Presence of Concurrent Type 2 Diabetes and NAFLD
An analysis of 80 worldwide studies shows the ever-growing prevalence of patients with both type two diabetes and nonalcoholic fatty liver disease. This prevalence varies in different regions of the globe.
NASH Leads Liver Disease “Economic Tsunami” in the US
A white paper presented by the University of Oxford’s visiting professor of hepatology, Dr. Stephen A. Harrison, examines the economic impact of the liver disease epidemic on the US healthcare system.
Phase II clinical trial shows promise for type 2 diabetes
Fantastic news out of Amsterdam University Medical Center! A phase II study has reported duodenal mucosal resurfacing has promising results for type 2 diabetes patients, showing lasting improvements for insulin resistance markers and glycemic control – all without bariatric surgery.
Combined tests help identify NASH-related fibrosis
Researchers at Newcastle University in the UK found that Fibrosis-4 indexes coupled with enhanced liver fibrosis tests can identify NASH-related advanced fibrosis while reducing indeterminate results rate. Take a look at their compelling study.